HLA-DRB1∗0405 is the Predominant Allele in Brazilian Patients With Vogt-Koyanagi-Harada Disease

Goldberg, Anna Carla; Yamamoto, Jiro; Chiarella, Josely Marchi; Marin, Maria Lúcia Carnevale; Sibinelli, Maria Auxiliadora; Neufeld, Richard R.; Hirata, Carlos Eduardo; Olivalves, Edilberto; Kalil, Jorge

doi:10.1016/s0198-8859(97)00265-6

Cited by 74 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Goldberg et al showed that HLA-DRB1*0405 is also the predominant susceptibility allele in Brazilian patients, a very ethnic heterogeneous population. In that study, the different alleles originally proposed to be associated with VKH were present separately, reinforcing the importance of HLA-DRB1*0405 as the main susceptibility allele to VKH (18) . The importance of this allele in susceptibility to the development of VKH was reinforced by Damico et al, who showed that patients bearing HLA-DRB1*0405 recognized a larger melanocyte-derived peptide repertoire than HLA-matched control subjects (12) .…”

Section: Immunogeneticsmentioning

confidence: 57%

New insights into Vogt-Koyanagi-Harada disease

Damico

Bezerra²,

Silva³

et al. 2009

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Section: Immunogeneticsmentioning

confidence: 57%

New insights into Vogt-Koyanagi-Harada disease

Damico

Bezerra²,

Silva³

et al. 2009

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…The disease has the strongest association with the HLA-DR4 allele in different groups of patients, but other alleles have also shown themselves to be determinants of the syndrome's emergence, including HLA-DR53, DQ54, DQ7 and DR1 7,19 . The allele subtypes that have the most significant associations with the disease are HLA-DRB1*0410 and HLA-DRB1*0405, with the second of these being most common in different populations, including the Brazilian population 20 . Many authors have been attempting to elucidate the cause or "trigger" that results in the immune system disorder and emergence of the syndrome.…”

Section: Etiology and Pathogenesismentioning

confidence: 99%

Síndrome de Vogt-Koyanagi-Harada e o seu acometimento multissistêmico

Mota¹,

Santos²

2010

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Vogt-Koyanagi-Harada's syndrome is a rare disease that affects tissues containing melanocytes, such as the eyes, central nervous system, inner ear and skin. Some ethnic groups have a higher probability of developing the disease, including Asians, Indians and Latin Americans and females are affected more often. Methods: Literature was reviewed in books, articles published on the internet and papers available in the online databases MEDLINE, LILACS and SciELO. Texts were selected that focused on otorhinolaryngological symptoms. Literature review: The disease probably has autoimmune etiology, with aggression occurring on the surface of melanocytes by promoting inflammatory reaction in which T lymphocytes predominate. The allele most often found in association with this disease is HLA DRB1*0405. Clinical manifestations are divided into four stages: prodromal, uveitic, chronic and recurrent. Otorhinolaryngological symptoms occur during the uveitic stage and are characterized by bilateral sensorineural hearing loss, tinnitus and vestibular symptoms. Diagnosis is made according to the diagnostic criteria for the disease. Treatment is primarily with corticosteroids. Conclusions: It is important that professionals in other specialties are able to recognize Vogt-Koyanagi-Harada's syndrome, because late diagnosis can lead to ocular and cutaneous sequelae.

show abstract

“…Aisenbrey and coworkers [20] suggest that the described ocular findings of VKH disease may represent a component of a syndrome consisting also of melanoma-associated hypopigmentation. Within the framework of current concepts of immunity in patients with cutaneous pigmented malignant melanoma and VKH, the long recurrence-free interval might support the hypothesis of an immune process against melanocytes [14][15][16][17]. The use of immunosuppressive therapy in the treatment of VKH and its potential influence on the development of metastatic disease should be considered.…”

Section: Discussionmentioning

confidence: 99%